Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment
BJU International · 2025-08 · 136 (2) · 245-253
DOI: 10.1111/bju.16727 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 14.04.2025. Verfasst von Ivo I de Vos und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Watchful Waiting, Overtreatment. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting Wetenschappelijk Onderzoek Prostaatkanker.
Abstract (Originalsprache)
Objectives
To present the long‐term outcomes of men with Grade Group (GG) 1 prostate cancer (PCa), included in the Prostate Cancer Research International Active Surveillance (PRIAS) study, and to assess the effect of the inclusion of magnetic resonance imaging (MRI) within the active surveillance (AS) protocol. Patients and Methods The PRIAS study is a multicentre, prospective, web‐based cohort study monitoring patients on AS. In total, 8910 men with GG1 PCa were followed in 169 centres worldwide. The cumulative incidences of definitive treatment, metastasis and PCa‐specific mortality (PCSM) were estimated using competing risk analyses. Additionally, multivariable analysis was performed to assess the risk of reclassification, stratified by MRI performed around the time of diagnosis.
Results
The cumulative incidence of definitive treatment 15 years post‐diagnosis was 55% (95% confidence interval [CI] 53–57). For metastasis, the 15‐year cumulative incidence was 2.7% (95% CI 1.5–4.4). Eight men of died from PCa, resulting in a 15‐year cumulative PCSM incidence of 0.23% (95% CI 0.09–0.54). Compared to men with no MRI around the time of diagnosis, those who underwent MRI during the first 18 months of AS were associated with a significantly higher risk of reclassification to ≥GG2, while men with a positive MRI before diagnosis were associated with a higher risk of reclassification to GG2, but not to ≥GG3. Men with GG2 PCa on MRI‐targeted rebiopsy who underwent definitive treatment did not show a statistically significant higher risk of 5‐year disease recurrence compared to those who had GG1 PCa on last biopsy during AS.
Conclusions
Our study confirms the safety of AS for GG1 PCa, with low metastasis and PCSM rates over 15 years. Furthermore, the inclusion of MRI in AS prompts increased detection of GG2, leading to increased treatment rates despite similar short‐term risks. To minimise overtreatment, expanding eligibility for AS and the uptake of AS in men with favourable GG2 PCa is crucial to address the stage shift resulting from the increased accuracy of MRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Urology, Sint Franciscus Hospital, Rotterdam, The Netherlands.
- Department of Urology, Hospital Universitario de Navarra, Pamplona, Spain.
- Department of Urology, Martini Klinik, Hamburg, Germany.
- Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Ivo I de Vos, Antti S Rannikko, Diederik M Somford, Sebastiaan Remmers, Monique J Roobol
Förderung
- Stichting Wetenschappelijk Onderzoek Prostaatkanker
Zitieren
APA
de Vos, I. I., Marenghi, C., Badenchini, F., Boevé, E. R., Lozano-Uruñuela, F., Graefen, M., Rannikko, A. S., Staerman, F., Sugimoto, M., Kato, T., Somford, D. M., Frydenberg, M., Bangma, C. H., Remmers, S., Roobol, M. J., & Prostate Cancer Research International: Active Surveillance (PRIAS) consortium (2025). Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU International, 136(2), 245-253. https://doi.org/10.1111/bju.16727
Vancouver
de Vos II, Marenghi C, Badenchini F, Boevé ER, Lozano-Uruñuela F, Graefen M, et al. Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU International. 2025;136(2):245-253. doi:10.1111/bju.16727
BibTeX
@article{deVos2025,
author = {de Vos, Ivo I and Marenghi, Cristina and Badenchini, Fabio and Boevé, Egbert R and Lozano-Uruñuela, Francisco and Graefen, Markus and Rannikko, Antti S and Staerman, Frederic and Sugimoto, Mikio and Kato, Takuma and Somford, Diederik M and Frydenberg, Mark and Bangma, Chris H and Remmers, Sebastiaan and Roobol, Monique J and Prostate Cancer Research International: Active Surveillance (PRIAS) consortium, Prostate Cancer Research International: Active Surveillance (PRIAS) consortium},
title = {Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment},
journal = {BJU International},
year = {2025},
volume = {136},
number = {2},
pages = {245--253},
doi = {10.1111/bju.16727}
}
EUVIMED